MAGEA3 and neoplasm: We validated PS-TRACT on experimentally observed cross-reactive peptides, including tumoral and microbial epitopes [145], and the TTN peptide ESDPIVAQY which was found to be the off-tumor target in cases of fatal myocarditis in patients receiving TCR-T cells directed at the MAGEA3 epitope EVDPIGHLY [146] (Additional file 2:Fig S8A).